BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers Symposium

Oral presentation for RATIONALE 305 showed improved survival and manageable safety profile for tislelizumab and chemotherapy in gastric or gastroesophageal junction cancer with PD-L1 expression BeiGene

Related Keywords

China ,Beijing ,Cambridge ,Cambridgeshire ,United Kingdom ,United States ,America ,Kevin Mannix ,Mark Lanasa ,Kyle Blankenship ,Exchange Commission ,European Union ,Cancers Symposium ,Chief Medical Officer ,Solid Tumors ,First Line Treatment ,Advanced Gastric ,Gastroesophageal Junction Adenocarcinoma ,Abstract Session ,License Applications ,Overall Survival ,Overall Response Rate ,Blinded Independent Review Committee ,Progression Free Survival ,Switzerland Beijing ,Private Securities Litigation Reform Act ,Beigene ,Presents ,Research ,Rom ,Tislelizumab ,Lobal ,Development ,Program ,023 ,Disco ,Gastrointestinal ,Cancers ,Symposium ,